Impact of Cardio-Selective Beta-Blockers on Infarct Size After Acute Myocardial Infarction
Introduction: The effect of intravenous beta-blockers on the extent of the necrotic area, after primary percutaneous transluminal coronary angioplasty (PTCA), for acute myocardial infarction is not well established. Purpose: The present study aims to investigate, whether the early intravenous administration of landiolo
| Condition(s) | STEMI |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Introduction: The effect of intravenous beta-blockers on the extent of the necrotic area, after primary percutaneous transluminal coronary angioplasty (PTCA), for acute myocardial infarction is not well established. Purpose: The present study aims to investigate, whether the early intravenous administration of landiolol, a highly cardioselective b-blocker, reduces the extent of the necrotic area after ST-elevation myocardial infarction (STEMI). Methods: This prospective observational cohort study will enroll patients presenting with STEMI, who undergo primary PCI and receive either intravenous landiolol or standard oral β-blocker therapy, in accordance with current European Society of Cardiology (ESC) guidelines. Eligibility will be determined by predefined inclusion and exclusion criteria |
| Who can participate | Inclusion Criteria: * Age between 18 and 80 years * Patients with electrocardiogram showing ST-segment elevation ≥2 mm in 2 or more contiguous leads for more than 30 minutes * Estimated time from symptom onset to reperfusion ≤12 hours * Patients scheduled to undergo primary angioplasty * Patients who have signed a consent form Exclusion Criteria: * Patients receiving chronic medication with beta-adrenergic blockers * Patients with a previous myocardial infarction * Persistent systolic blood pressure \<90 mmHg * Persistent heart rate \<55 beats per minute * Patients with Killip class III (acute pulmonary edema) or IV (cardiogenic shock) on initial examination * 12-lead electrocardiogram with PR interval \>200 milliseconds * 12-lead electrocardiogram showing second- or third-degree atriovent |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Lead sponsor | Aristotle University Of Thessaloniki |
| Locations | Thessaloniki, Thessaloniki, Greece |
| Start date | 2024-11-13 |
| NCT ID | NCT07293832 |
| Official listing | https://clinicaltrials.gov/study/NCT07293832 |